Linda Lowes

8.5k total citations · 3 hit papers
128 papers, 2.9k citations indexed

About

Linda Lowes is a scholar working on Molecular Biology, Genetics and Psychiatry and Mental health. According to data from OpenAlex, Linda Lowes has authored 128 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Molecular Biology, 44 papers in Genetics and 29 papers in Psychiatry and Mental health. Recurrent topics in Linda Lowes's work include Muscle Physiology and Disorders (62 papers), Neurogenetic and Muscular Disorders Research (43 papers) and Cerebral Palsy and Movement Disorders (27 papers). Linda Lowes is often cited by papers focused on Muscle Physiology and Disorders (62 papers), Neurogenetic and Muscular Disorders Research (43 papers) and Cerebral Palsy and Movement Disorders (27 papers). Linda Lowes collaborates with scholars based in United States, United Kingdom and Italy. Linda Lowes's co-authors include Lindsay N. Alfano, Jerry R. Mendell, Katherine Berry, Sarah L. Westcott, Samiah Al-Zaidy, Richard Shell, Kelly J. Lehman, Jerry R. Mendell, Pamela Richardson and M. Iammarino and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Linda Lowes

116 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Longitudinal effect of eteplirsen versus historical control on ambulation in D uchenne muscular dystrophy

2015 372 citations Jerry R. Mendell, Nathalie Goemans et al. profile →
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy

2020 264 citations Jerry R. Mendell, Zarife Sahenk et al. profile →
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy

2021 173 citations Jerry R. Mendell, Samiah Al-Zaidy et al. profile →

Peers

Countries citing papers authored by Linda Lowes

Since Specialization

Citations

This map shows the geographic impact of Linda Lowes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Lowes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Lowes more than expected).

Fields of papers citing papers by Linda Lowes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Lowes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Lowes. The network helps show where Linda Lowes may publish in the future.

Co-authorship network of co-authors of Linda Lowes

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Lowes. A scholar is included among the top collaborators of Linda Lowes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Lowes. Linda Lowes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Psychometric evaluation of the PROMIS parent proxy mobility item bank for use in Duchenne muscular dystrophy 2024 ·Developmental Medicine & Child Neurology ·Linda Lowes, (unknown), Lindsay N. Alfano, Natalie F. Reash, M. Iammarino, (unknown), (unknown)	0
2	425P Five-year outcomes with delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD): a phase 1/2a study 2024 ·Neuromuscular Disorders ·(unknown), (unknown), Linda Lowes, (unknown), (unknown), (unknown), (unknown), Jing Jin, (unknown), (unknown), Jacob Elkins, (unknown)	1
3	Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study 2024 ·BMC Neurology ·(unknown), Lindsay N. Alfano, Jordi Díaz‐Manera, Linda Lowes, Tahseen Mozaffar, Katherine D. Mathews, Conrad C. Weihl, Matthew Wicklund, Man Hung, Jeffrey Statland, Nicholas E. Johnson, Doris G. Leung, Peter B. Kang, (unknown), John Vissing, (unknown), (unknown)	0
4	Toward patient-centered treatment goals for duchenne muscular dystrophy: insights from the “Your Voice” study 2023 ·Orphanet Journal of Rare Diseases ·Carolyn E. Schwartz, (unknown), James Valentine, N. Miller, Linda Lowes, Danielle L. Edwards, (unknown), (unknown), (unknown), (unknown), (unknown)	3
5	Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial 2023 ·Muscle & Nerve ·Jerry R. Mendell, Zarife Sahenk, Kelly J. Lehman, Linda Lowes, Natalie F. Reash, M. Iammarino, Lindsay N. Alfano, Sarah Lewis, Kathleen Church, Richard Shell, Rachael A. Potter, Danielle A. Griffin, Mark Hogan, Shufang Wang, Stefanie Mason, (unknown), Louise R. Rodino‐Klapac	37
6	P314: Long-term safety and sustained functional benefit in patients with DMD 4 years post-treatment with delandistrogene moxeparvovec: A phase 1/2a study* 2023 ·SHILAP Revista de lepidopterología ·Erin O’Rourke, Jerry R. Mendell, Zarife Sahenk, Kelly J. Lehman, Linda Lowes, Natalie F. Reash, M. Iammarino, Lindsay N. Alfano, Sarah J. Lewis, Kathleen Church, Richard Shell, Rachael A. Potter, (unknown), Mark Hogan, Shufang Wang, Stefanie Mason, (unknown), Louise R. Rodino‐Klapac	1
7	130 Safety, β-sarcoglycan expression and functional outcomes from systemic gene transfer of rAAVrh74.MHCK7.SGCB in LGMD2E/R4 2022 ·Journal of Neurology Neurosurgery & Psychiatry ·Louise R. Rodino‐Klapac, Eric R. Pozsgai, Sarah J. Lewis, (unknown), (unknown), Kelly J. Lehman, Kathleen Church, Linda Lowes, (unknown), Jerry R. Mendell	0
8	260 Gene transfer with rAAVrh74.MHCK7.SGCB increased β-sarcoglycan expression in LGMD type 2E patients 2022 ·Journal of Neurology Neurosurgery & Psychiatry ·James W. Richardson, Louise R. Rodino‐Klapac, Eric R. Pozsgai, Sarah Lewis, (unknown), Kelly J. Lehman, Kathleen Church, N. Miller, M. Iammarino, Linda Lowes, (unknown)	0
9	Phase 1/2a Trial of SRP-9001 in Patients with Duchenne Muscular Dystrophy: 3-Year Safety and Functional Outcomes (S23.004) 2022 ·Neurology ·Jerry R. Mendell, Zarife Sahenk, Kelly J. Lehman, (unknown), Linda Lowes, Natalie F. Reash, M. Iammarino, Lindsay N. Alfano, (unknown), Sarah Lewis, Kathleen Church, Richard Shell, Rachael A. Potter, Danielle A. Griffin, Eric R. Pozsgai, Mark Hogan, (unknown), Kathryn Giblin, Louise R. Rodino‐Klapac	1
10	Comparison of strength testing modalities in dysferlinopathy 2022 ·Muscle & Nerve ·Natalie F. Reash, M. James, Lindsay N. Alfano, Anna Mayhew, Marni Jacobs, M. Iammarino, (unknown), Chikako Sakamoto, (unknown), Hiroyuki Yajima, Tina Duong, (unknown), Richard Gee, Diana Bharucha‐Goebel, Elena Bravver, Madoka Mori‐Yoshimura, Kate Bushby, Laura Rufibach, Volker Straub, Linda Lowes	3
11	First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases 2021 ·SHILAP Revista de lepidopterología ·Laurent Servais, (unknown), (unknown), Craig M. McDonald, (unknown), Linda Lowes, (unknown), Francesca Cerreta, (unknown)	41
12	Use of the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) in X-Linked Myotubular Myopathy: Content Validity and Psychometric Performance 2020 ·Journal of Neuromuscular Diseases ·Tina Duong, Gale Harding, Sally Mannix, (unknown), Dawn Phillips, Lindsay N. Alfano, Carsten G. Bönnemann, C. Lilien, Linda Lowes, Laurent Servais, (unknown), (unknown), Emma S. James, Mojtaba Noursalehi, Suyash Prasad, Salvador Rico, Deborah A. Bilder	7
13	Activity monitoring in neuromuscular disease: Successes, challenges, and a path forward (P5.6-016) 2019 ·Neurology ·Linda Lowes, N. Miller, M. Iammarino, (unknown), Lindsay N. Alfano	1
14	AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort 2019 ·Journal of Neuromuscular Diseases ·Samiah Al-Zaidy, Stephen J. Kolb, Linda Lowes, Lindsay N. Alfano, Richard Shell, (unknown), Sukumar Nagendran, Douglas M. Sproule, Douglas E. Feltner, Courtney Wells, Francis G. Ogrinc, Melissa Menier, James L’Italien, W. David Arnold, John T. Kissel, Brian K. Kaspar, Jerry R. Mendell	128
15	Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History 2017 ·Journal of Neuromuscular Diseases ·T. Bernard Kinane, Oscar H. Mayer, Petra W. Duda, Linda Lowes, (unknown), Jerry R. Mendell	48
16	Modeling functional decline over time in sporadic inclusion body myositis 2016 ·Muscle & Nerve ·Lindsay N. Alfano, Han Yin, Igor Dvorchik, (unknown), Kevin M. Flanigan, Jerry R. Mendell, Linda Lowes	11
17	Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Clinical Update and Longitudinal Comparison to External Controls on Six-Minute Walk Test (6MWT) (S28.001) 2016 ·Neurology ·Jerry R. Mendell, Nathalie Goemans, Louise R. Rodino‐Klapac, Zarife Sahenk, Linda Lowes, Lindsay N. Alfano, Katherine Berry, (unknown), Sarah Lewis, Kim Shontz, James Shao, Petra W. Duda, (unknown), Frédéric Schnell, (unknown), Bruce M. Wentworth, Edward M. Kaye, Eugenio Mercuri, (unknown)	1
18	A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design 2016 ·Molecular Genetics and Metabolism ·(unknown), Haiyan Fu, Douglas M. McCarty, Kelly McNally, (unknown), Nicholas Zumberge, Lisa Martin, Shawn C. Aylward, Lindsay N. Alfano, Katherine Berry, Linda Lowes, Marco Corridore, (unknown), Kim L. McBride, Kevin M. Flanigan	40
19	Games for Therapy: Defining a Grammar and Implementation for the Recognition of Therapeutic Gestures 2013 ·Foundations of Digital Games ·(unknown), Roger Crawfis, Lynne V. Gauthier, Lise Worthen‐Chaudhari, Linda Lowes, (unknown), (unknown)	7
20	Conservative Management of Congenital Muscular Torticollis: An Evidence-Based Algorithm and Preliminary Treatment Parameter Recommendations 2013 ·Physical & Occupational Therapy In Pediatrics ·(unknown), (unknown), (unknown), (unknown), Helen Carey, Linda Lowes	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact